Clinical Trials on Locoregionally Advanced in Korea, Democratic People's Republic of

Total 438 results

AstraZeneca

Completed

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

Advanced Solid Tumors

Japan, Korea, Republic of, Taiwan
Novartis Pharmaceuticals

Recruiting

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Advanced Solid Tumors Which Are cMET-dependent

Germany, Korea, Republic of, Belgium, Italy, Singapore, United States, Denmark, Spain, France, Canada
Amgen

Recruiting

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Taiwan, Australia, United States, Japan, Canada, Korea, Republic of, Poland
Genentech, Inc.

Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

Metastatic Prostate Cancer | Advanced Prostate Cancer

Korea, Republic of, United States, Australia
Amgen

Recruiting

Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Spain, United Kingdom, Australia, Germany, France, Japan, Canada
Eisai Inc.
H3 Biomedicine Inc.

Terminated

Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101

Lymphoma | Advanced Solid Tumors

United States, Spain, France, Korea, Republic of, United Kingdom
J Ints Bio

Recruiting

A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

EGFR Mutant Advanced Non-small Cell Lung Cancer

Korea, Republic of, United States, Thailand
AstraZeneca

Completed

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

Advanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung Cancer

Belgium, United States, Korea, Republic of, Taiwan, United Kingdom, Netherlands
Novartis Pharmaceuticals

Terminated

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Advanced Malignancies

Taiwan, Netherlands, Italy, Korea, Republic of, Japan, United States, Switzerland, Canada, Singapore
Bristol-Myers Squibb

Active, not recruiting

A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors

Advanced Cancer

United States, Spain, Argentina, Belgium, Korea, Republic of, Japan
Puma Biotechnology, Inc.

Completed

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Breast Neoplasms | Advanced Breast Cancer | Advanced Malignant Solid Tumors

United States, Belgium, China, Hong Kong, Canada, Korea, Republic of, India, Poland, Ukraine
Novartis Pharmaceuticals

Terminated

Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients

Advanced Gastric Cancer

Spain, Belgium, France, Italy, United States, Korea, Republic of, Japan, Germany
Pfizer

Completed

Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

Korea, Republic of, Japan, China
Novartis Pharmaceuticals

Completed

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

France, Netherlands, Spain, Canada, Singapore, Germany, Korea, Republic of, Australia, Belgium, Switzerland, Italy, United States
Boston Pharmaceuticals

Completed

Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

Advanced Nonhaematologic Malignancies

United States, Korea, Republic of, Taiwan, France, Hong Kong, Belgium, Spain
Novartis Pharmaceuticals

Active, not recruiting

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments

Advanced Solid Tumors

China, Belgium, Italy, Hungary, Germany, Spain, Canada, Czechia, France, Poland, Korea, Republic of, Hong Kong, Netherlands, Switzerland, Thailand, Taiwan, United States
MedImmune LLC

Active, not recruiting

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

Selected Advanced Solid Tumors

Italy, Spain, United States, France, Korea, Republic of, Taiwan, Australia, Netherlands, Portugal
AstraZeneca

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1)

ER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)

United States, United Kingdom, Korea, Republic of, Australia, Spain
Jiangsu HengRui Medicine Co., Ltd.
Atridia Pty Ltd.

Recruiting

A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors

Advanced Solid Tumors

China, Korea, Republic of, Taiwan, United States, Australia
UCB BIOSCIENCES GmbH
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease

Advanced Parkinson's Disease

Australia, Korea, Republic of, Malaysia, Singapore, Taiwan
AstraZeneca
Parexel

Active, not recruiting

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

Advanced Haematological Malignancies

Spain, United States, Canada, Korea, Republic of, Poland, Australia, France, United Kingdom, Ireland
Ningbo Newbay Technology Development Co., Ltd

Recruiting

A Study of NB003 in Patients With Advanced Malignancies

Advanced Solid Tumor

United States, Spain, China, Korea, Republic of, France, United Kingdom
Novartis Pharmaceuticals

Completed

Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer

Advanced HER2-positive Breast Cancer or Gastric Cancer

Taiwan, Netherlands, Italy, United States, Belgium, United Kingdom, Korea, Republic of, France, Spain
Novartis Pharmaceuticals

Completed

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Advanced Non-small Cell Lung Cancer

Spain, Canada, Germany, Korea, Republic of, Taiwan, United States, Japan, Netherlands, Singapore
BeiGene

Enrolling by invitation

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Advanced Malignancies

China, Taiwan, Korea, Republic of, Turkey
Calico Life Sciences LLC
AbbVie

Recruiting

First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors

Advanced Solid Tumors Cancer

Korea, Republic of, Taiwan, Spain, United States, France, Japan, Israel
Hoffmann-La Roche
Tempest Therapeutics; Adagene Inc; Immune-Onc Therapeutics; NiKang Therapeutics...

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Advanced Liver Cancers

Korea, Republic of, Taiwan, United States, Israel, China, France, New Zealand
Merck Sharp & Dohme LLC

Active, not recruiting

A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18)

Advanced or Metastatic Solid Tumors

Chile, Hungary, Korea, Republic of, South Africa, Spain, Japan
UCB BIOSCIENCES GmbH
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease

Advanced Idiopathic Parkinson's Disease

Korea, Republic of, United States, Malaysia, Singapore, Taiwan
Bayer

Recruiting

A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, United Kingdom, Korea, Republic of, Japan, Spain, Belgium, China
AstraZeneca

Active, not recruiting

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

Locally Advanced or Metastatic Solid Tumours

United States, Spain, Canada, Korea, Republic of
BeiGene

Completed

Study of Tislelizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer

Locally Advanced or Metastatic Urothelial Bladder Cancer

Korea, Republic of, China
Curis, Inc.

Completed

A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas

Advanced Solid Tumors or Lymphomas

United States, Spain, Korea, Republic of, United Kingdom
AstraZeneca

Completed

Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients (BEECH)

Advanced or Metastatic Breast Cancer | ER+ve Advanced or Metastatic Breast Cancer

Canada, France, Korea, Republic of, Czechia, Peru, United Kingdom, Spain, Japan, Mexico, Singapore, Bulgaria
Novartis Pharmaceuticals

Completed

Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC

Advanced Hepatocellular Carcinoma

Taiwan, Canada, Italy, Korea, Republic of, Hong Kong, Germany, China, France
Nuvalent Inc.

Recruiting

A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

Metastatic Solid Tumor | Locally Advanced Solid Tumor

Canada, United States, Korea, Republic of, Taiwan, Japan, Spain, Australia, Belgium, United Kingdom, France, Italy, Netherlands, Singapore, Germany
Daiichi Sankyo
AstraZeneca

Recruiting

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Metastatic Cancer | Advanced Cancer

Spain, Italy, United States, Korea, Republic of, Belgium, France, Australia, Japan, Taiwan, United Kingdom
Astellas Pharma Global Development, Inc.
Merck Sharp & Dohme LLC

Completed

A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States, Korea, Republic of, Taiwan, Portugal, Spain, United Kingdom, Italy, Canada, Japan
Novartis Pharmaceuticals

Completed

Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) (TNBC)

Advanced Triple Negative Breast Cancer (TNBC) With High TAMs

France, Italy, Austria, Taiwan, United States, Spain, Australia, Korea, Republic of, Belgium, Germany, Hong Kong, Turkey
Turning Point Therapeutics, Inc.
Zai Lab (Shanghai) Co., Ltd.

Recruiting

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Locally Advanced Solid Tumors | Metastatic Solid Tumors

United States, China, Japan, Australia, Belgium, Canada, Denmark, France, Germany, Hong Kong, Hungary, Italy, Korea, Democratic People's Republic of, Korea, Republic of, Netherlands, Poland, Singapore, Spain, Taiwan, United Kingdom
Daiichi Sankyo, Inc.

Completed

CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer

Liver Neoplasms | Advanced Hepatocellular Carcinoma | Liver Cancer | Hepatic Cancer

Korea, Republic of, Taiwan, United States, Japan
MedImmune LLC

Active, not recruiting

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

Advanced Solid Tumors

United States, Spain, Belgium, Italy, Korea, Republic of, Canada, Australia, Hungary, United Kingdom, France, New Zealand
GI Innovation, Inc.
Merck Sharp & Dohme LLC

Recruiting

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

Melanoma | Sarcoma | Renal Cell Carcinoma | Cervical Cancer | Urinary Bladder Cancer | Vulvar Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Vaginal Cancer | Microsatellite Stable...

Korea, Republic of, United States
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

Canada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
Novartis Pharmaceuticals

Completed

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3 | Squamous Lung Cancer With FGFR1 Amplification | Bladder Cancer With FGFR3 Mutation or Fusion | Advanced Solid Tumors With FGFR1 Amplication | Advanced Solid Tumors With FGFR2 Amplication | Advanced Solid Tumors With FGFR3 Mutation

France, Spain, Taiwan, Germany, Netherlands, Singapore, United States, Australia, Korea, Republic of, Thailand, Israel, Italy, Turkey, Austria
MedImmune LLC

Completed

A Phase 1/2 Study to Evaluate MEDI4736

Advanced Solid Tumors

United States, Germany, Italy, United Kingdom, Belgium, Canada, Korea, Republic of, Taiwan, France
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

FGFR2 Gene Mutation | Advanced Cholangiocarcinoma

United States, Belgium, Germany, Italy, Korea, Republic of, Russian Federation, Singapore, Spain, Taiwan, Thailand, United Kingdom
Impact Therapeutics, Inc.

Recruiting

IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer

Small Cell Lung Cancer | Advanced Solid Tumours

Taiwan, Korea, Republic of, China, Australia, United States
AbbVie

Active, not recruiting

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

Advanced Solid Tumors Cancer

United States, Belgium, France, Italy, Japan, Korea, Republic of, Netherlands, Taiwan, Finland
AbbVie

Active, not recruiting

A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

Advanced Solid Tumors Cancer

United States, Australia, Canada, France, Japan, Korea, Republic of, Spain

Clinical Trials on Locoregionally Advanced in Korea, Democratic People's Republic of

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations